Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. Am Heart J 2011 Mar;161(3):494-9

Date

03/12/2011

Pubmed ID

21392603

DOI

10.1016/j.ahj.2010.12.003

Scopus ID

2-s2.0-79952377060 (requires institutional sign-in at Scopus site)   38 Citations

Abstract

BACKGROUND: Kawasaki disease (KD) is a multisystem vasculitis affecting coronary arteries in children. Patients, refractory to standard treatment with intravenous immunoglobulin and aspirin, show higher rates of coronary artery dilation. Early tumor necrosis factor α receptor antagonism in KD may provide effective adjunctive therapy.

STUDY DESIGN: The EATAK trial is a multicenter, double-blind, randomized, and placebo-controlled trial intended to assess the efficacy of etanercept in reducing the intravenous immunoglobulin refractory rate during treatment of acute KD. Each arm will enroll 110 patients who will receive 3 doses of study drug over 2 weeks in conjunction with standard therapy. Coronary artery dilation parameters will serve as secondary end points.

DISCUSSION: The EATAK trial will test a new paradigm for treatment of acute KD involving tumor necrosis factor α antagonism by etanercept.

Author List

Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E

Author

Edward C. Kirkpatrick DO Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Coronary Vessels
Dilatation, Pathologic
Endpoint Determination
Etanercept
Humans
Immunoglobulin G
Immunoglobulins, Intravenous
Immunologic Factors
Receptors, Tumor Necrosis Factor
Research Design